Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anticancer agent 199 (Compound G-4) is a derivative of the cyclin-dependent kinase inhibitor Rocovitine [1]. It prompts apoptosis in triple negative breast cancer (TNBC) cells through the mitochondrial pathway by inhibiting the EGFR, AKT, and MAPK pathways. Furthermore, it triggers Ferroptosis by suppressing LCN2 and reduces TNBC cell viability and migration while inducing S phase cell cycle arrest.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Anticancer agent 199 (Compound G-4) is a derivative of the cyclin-dependent kinase inhibitor Rocovitine [1]. It prompts apoptosis in triple negative breast cancer (TNBC) cells through the mitochondrial pathway by inhibiting the EGFR, AKT, and MAPK pathways. Furthermore, it triggers Ferroptosis by suppressing LCN2 and reduces TNBC cell viability and migration while inducing S phase cell cycle arrest. |
Molecular Weight | 556.12 |
Formula | C29H39ClFN7O |
Cas No. | 2422001-24-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.